Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

NASDAQ: HMSY

  • Home
  •  
  • NASDAQ: HMSY



  • Most Read
  • Latest Comments
  • Major U.S healthcare company invests $11m in MedAdvisor at a premium
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Major U.S healthcare company invests $11m in MedAdvisor at a premium
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Major U.S healthcare company invests $11m in MedAdvisor at a premium
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Major U.S healthcare company invests $11m in MedAdvisor at a premium
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Major U.S healthcare company invests $11m in MedAdvisor at a premium
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • MedAdvisor reports strong quarter thanks to US vaccine programs and Aus transaction fees
    MedAdvisor reports strong quarter thanks to US vaccine programs and Aus transaction fees
    • News

  • MedAdvisor’s PlusOne platform wins Queensland healthcare pilot contract
    MedAdvisor’s PlusOne platform wins Queensland healthcare pilot contract
    • News

  • MedAdvisor engaged with $4m deal to promote COVID-19 vaccination
    MedAdvisor engaged with $4m deal to promote COVID-19 vaccination
    • News

  • Three Tech Stocks Under 10c Positioned to Capitalise on Global Coronavirus Shutdowns
    Three Tech Stocks Under 10c Positioned to Capitalise on Global Coronavirus Shutdowns
    • Opinion

  • Major U.S healthcare company invests $11m in MedAdvisor at a premium
    Major U.S healthcare company invests $11m in MedAdvisor at a premium
    • News

  • Major U.S healthcare company invests $11m in MedAdvisor at a premium
    • News

    Major U.S healthcare company invests $11m in MedAdvisor at a premium

    Australian medtech company MedAdvisor (ASX: MDR) has received a major boost in confidence following an oversubscribed capital raise which included an $11m investment from U.S healthcare solutions provider HMS (NASDAQ: HMSY).  The investment from HMS comes alongside a further $6m raised from institutional investors bringing their total funds raised to $17m, all at an Offer

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.